Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer
Oppenheimer said that a new analysis conducted by Veru (VERU) on mortality rates in a phase 3 trial of its COVID-19 therapy sabizabulin assuages concerns and will lead to an EUA.
Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer
Oppenheimer said that a new analysis conducted by Veru (VERU) on mortality rates in a phase 3 trial of its COVID-19 therapy sabizabulin assuages concerns and will lead to an EUA.